Literature DB >> 1890364

IgM antibodies to native phenolic glycolipid-I in contacts of leprosy patients in Venezuela: epidemiological observations and a prospective study of the risk of leprosy.

M Ulrich1, P G Smith, C Sampson, M Zuniga, M Centeno, V Garcia, X Manrique, A Salgado, J Convit.   

Abstract

In a randomized, double-blind vaccine trial in Venezuela, about 29,000 contacts of leprosy patients have been vaccinated with either a mixture of heat-killed Mycobacterium leprae and BCG or BCG alone, and are being re-surveyed annually to detect new cases of leprosy. All contacts had a serum sample collected at the time of entry into the trial, and 13,020 of these sera have been analyzed for antibodies to phenolic glycolipid-I (PGL-I). Antibody levels have been related to various characteristics of the contacts and to their risk of developing leprosy in the following 4 years. A strong association was found between PGL-I antibody level and the risk of developing leprosy, in spite of possible modification of the incidence rate induced by vaccination. Antibody levels were higher in females than in males, and declined progressively with age. Household contacts had higher levels than did non-household contacts, and levels were higher in individuals from the state in Venezuela which has the highest incidence of the disease. No substantial differences were found in antibody levels between contacts of multibacillary and paucibacillary patients, which may in part reflect the influence of treatment, and there was no clear association with the presence of BCG or lepromin scars or with skin-test responses to PPD and leprosy soluble antigen. The assay of antibodies to PGL-I seems unlikely to provide a sensitive or specific test for infection with M. leprae, and measuring PGL-I antibody levels as a screening procedure to identify those at high risk of developing leprosy is unlikely to be particularly useful in most leprosy control programs. Such assays may be useful for the epidemiological monitoring of changes in the intensity of infection with M. leprae in a community and for the study of carefully defined groups of contacts during some phases of control programs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1890364

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


  5 in total

1.  Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial.

Authors:  F Johannes Moet; David Pahan; Linda Oskam; Jan H Richardus
Journal:  BMJ       Date:  2008-03-10

2.  Detection of Mycobacterium leprae nasal carriers in populations for which leprosy is endemic.

Authors:  P R Klatser; S van Beers; B Madjid; R Day; M Y de Wit
Journal:  J Clin Microbiol       Date:  1993-11       Impact factor: 5.948

3.  Impact of PGL-I seropositivity on the protective effect of BCG vaccination among leprosy contacts: a cohort study.

Authors:  Nádia C Düppre; Luiz Antonio B Camacho; Anna M Sales; Ximena Illarramendi; José Augusto C Nery; Elizabeth P Sampaio; Euzenir N Sarno; Samira Bührer-Sékula
Journal:  PLoS Negl Trop Dis       Date:  2012-06-19

4.  A case of leprosy in Malawi. Making the final push towards eradication: a clinical and public health perspective.

Authors:  Cieron Roe; Lucy Sarah May
Journal:  Infect Dis Poverty       Date:  2016-09-02       Impact factor: 4.520

Review 5.  Anti-PGL-1 Positivity as a Risk Marker for the Development of Leprosy among Contacts of Leprosy Cases: Systematic Review and Meta-analysis.

Authors:  Maria Lucia F Penna; Gerson O Penna; Paula C Iglesias; Sonia Natal; Laura C Rodrigues
Journal:  PLoS Negl Trop Dis       Date:  2016-05-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.